Beta Bionics (BBNX) Cash from Operations (2024 - 2026)

Beta Bionics has disclosed Cash from Operations across 3 years of filings, most recently posting -$14.6 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 7.56% year-over-year to -$14.6 million; the TTM figure through Jun 2026 stood at -$55.8 million (up 2.87% YoY), while the FY2025 annual figure was -$50.9 million, down 5.49% from the prior year.
• Cash from Operations came in at -$14.6 million for Q2 2026 at Beta Bionics, up from -$23.8 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$8.6 million in Q4 2025 to a low of -$23.8 million in Q1 2026.
• Average Cash from Operations over 3 years is -$13.8 million, with a median of -$12.9 million recorded in 2024.
• The largest YoY upside for Cash from Operations was 39.58% in 2025 against a maximum downside of 64.48% in 2025.
• Over 3 years, Cash from Operations stood at -$14.3 million in 2024, then jumped by 39.58% to -$8.6 million in 2025, then sank by 69.49% to -$14.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$14.6 million in Q2 2026, -$23.8 million in Q1 2026, and -$8.6 million in Q4 2025.